Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)
Condition: Hepatitis C
MeSH terms: Hepatitis A; Hepatitis C; Hepatitis
Intervention: Grazoprevir; Elbasvir; Ribavirin; Sofosbuvir
Intervention description: GZR 100 mg is a component of the MK-5172A FDC tablet (also containing EBR 50 mg) and was taken q.d. by mouth in the morning.; EBR 50 mg is a component of the MK-5172A FDC tablet (also containing GZR 100 mg) and was taken q.d. by mouth in the morning.; RBV 200 mg capsules taken b.i.d. (morning and evening) by mouth at a total daily dose ranging from 800 mg to 1400 mg (total daily dose was based on participant body weight).; SOF 400 mg tablet taken q.d. by mouth in the morning with food.
Intervention MeSH terms: Ribavirin; Sofosbuvir; Grazoprevir
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 101.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      This is a randomized, multi-site, open-label trial of the co-administration of a fixed-dose
      combination (FDC) of EBR 50 mg + GZR (100 mg) (EBR/GZR) and SOF 400 mg, with and without RBV,
      in treatment-naïve (TN) and treatment-experienced (TE) participants with chronic HCV GT3
      infection with compensated cirrhosis.
    

Eligibility criteria:

        Inclusion Criteria:

          -  has HCV RNA (>= 10,000 IU/mL in peripheral blood) at screening

          -  has documented HCV GT3 (with no evidence of non-typeable or mixed GT infection)

          -  has compensated cirrhosis of the liver

          -  has liver imaging within 6 months of Day 1 with no evidence of hepatocellular
             carcinoma (HCC)

          -  is either HCV TN or TE (i.e., has documented prior virologic failure or intolerance to
             peg-interferon/ribavirin)

          -  is otherwise healthy as determined by medical history, physical examination,
             electrocardiogram (ECG), and clinical laboratory measurements

          -  has compensated cirrhosis of the liver

          -  is TN or TE (i.e., documented prior virologic failure or intolerance to
             peg-interferon/ribavirin)

          -  is not of reproductive potential, or agrees to not impregnate a partner or become
             pregnant for at least 2 weeks prior to the first dose of study drug, and for 7 months
             after the final dose of study drug (or longer if dictated by local regulations)

        Exclusion Criteria:

          -  has previously received one or more doses of a direct-acting antiviral (DAA)

          -  has evidence of decompensated liver disease

          -  is coinfected with hepatitis B (hepatitis B surface antigen [HBsAg] positive)

          -  has a recent (within 5 years) history of malignancy or is under evaluation for HCC or
             other suspected malignancy

          -  is currently or has participated (within past 30 days) in a study with an
             investigational compound

          -  has clinically-relevant drug or alcohol abuse within the past 12 months of screening

          -  is a female and is pregnant or breast-feeding

          -  is a male whose female partner is/are pregnant

          -  has any of the following:

          -  organ transplants

          -  poor venous access

          -  history of gastric surgery or malabsorption disorder

          -  current or history of clinically significant cardiac abnormalities or dysfunction

          -  chronic pulmonary disease

          -  hemoglobinopathy

          -  history of hospitalization within 3 months prior to enrollment

          -  medical or surgical condition that may result in need for hospitalization during the
             course of the study

          -  any condition requiring, or likely to require, chronic systemic administration of
             corticosteroids, tumor necrosis factor (TNF) antagonists, or other immunosuppresant
             drugs during the course of the study

          -  any condition, prestudy laboratory or ECG abnormality, or history of any illness,
             which could confound results of the study or pose additional risks in administering
             study drugs in the opinion of the investigator

          -  has a life-threatening serious AE (SAE) during the screening period

          -  has evidence of history of chronic hepatitis not caused by HCV